Xavier University and the Cincinnati District Office of the Food and Drug Administration (FDA) are working together with pharmaceutical manufacturers to protect public health at the 2013 FDA/Xavier Pharmalink Conference, March 11-14 at Xavier University.
The FDA has been continually challenged to protect patients from drug shortages and counterfeit drug products. Congress and the FDA recently addressed these growing concerns by passing one of the largest pieces of legislation that will enhance the safety and quality of drugs in the United States – “The FDA Safety and Innovation Act” (FDASIA). The FDA/Xavier University PharmaLink Conference will bring together members from the FDA Office of the Commissioner with leading companies such as Pfizer, Merck, and Eli Lilly to discuss implementation of this new legislation, and how it will impact current manufacturing practices of the pharmaceutical industry.
Xavier University collaborates with experts from the pharmaceutical industry and FDA leaders to foster innovation. Featured speakers of the 2013 PharmaLink Conference include:
• John Lechleiter: CEO, President and Chairman, Eli Lilly
• Steve Solomon: Office of the Commissioner, FDA
• Hussain Mooraj: Partner, Global Lead Life Sciences Supply Chain, Accenture
• Michael Davidson: Vice President, Pfizer
The FDA/Xavier University PharmaLink Conference is part of Xavier University’s mission to make a difference in the communities we serve. The PharmaLink Conference focuses on maintaining quality in a global pharmaceutical supply chain by creating real solutions for the pharmaceutical industry to put into action. Xavier University aims for results that will uphold the FDA mission to maintain safe, available, and affordable drugs for patients in the United States.